| Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues. | |
| | |
MedLine Citation:
|
PMID: 21058104 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
With greater and enthusiastic interests in pursuing adaptive design clinical trials, the pharmaceutical industry as a whole is in the midst of gaining better understanding of scientifically sound approaches. In light of the public's greater interests, the Basel Biometric Section (BBS) of the Austo-Swiss Region of the International Biometric Society held a spring conference on "Perspectives on the Use of Adaptive Designs in clinical trials" at Basel University, Basel, Switzerland (March 12, 2010). The conference opened with statistical considerations and issues of adaptive designs in clinical trials, followed by a panel discussion in which international representatives from industry, academia, and regulatory agencies participated. In addition, six presentations were given by individual research groups mainly focusing on adaptive design methodologies, some illustrated with examples. There are two parts in this special article capturing the morning session of the conference. Part I summarizes the highlights given at the statistical considerations and issues session and is presented here. Part II, capturing the panelists' perspectives given at the panel discussion session, can be found immediately following Part I. |
| | |
Authors:
|
Sue-Jane Wang |
Related Documents
:
|
12769104 - Genetic testing: policy issues for the new millennium. 20555584 - Optical interference coatings: introduction by the feature editors. 1110984 - Collective bargaining for radiologic technologists: organizational vehicles. 19760274 - Es kann die spur von unseren erdetagen--on pharmacologists and pharmacology. 21790694 - Evidence - competence - discourse: the theoretical framework of the multi-centre clinic... 19919234 - Contemporary orthodontic education. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of biopharmaceutical statistics Volume: 20 ISSN: 1520-5711 ISO Abbreviation: J Biopharm Stat Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9200436 Medline TA: J Biopharm Stat Country: England |
Other Details:
|
Languages: eng Pagination: 1090-7 Citation Subset: IM |
Affiliation:
|
Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. suejane.wang@fda.hhs.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new (15)N tracer method to determine N turnover and denitrification of Pseudomonas stutzeri.
Next Document: Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion.